76 related articles for article (PubMed ID: 9401829)
41. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
Diener HC
Cerebrovasc Dis; 1998; 8(3):172-81. PubMed ID: 9619701
[TBL] [Abstract][Full Text] [Related]
42. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group.
Grotta J
Stroke; 1997 Dec; 28(12):2338-46. PubMed ID: 9412611
[TBL] [Abstract][Full Text] [Related]
43. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.
Gajjar DA; LaCreta FP; Uderman HD; Kollia GD; Duncan G; Birkhofer MJ; Grasela DM
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):49S-58S. PubMed ID: 10850521
[TBL] [Abstract][Full Text] [Related]
44. Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics.
Page RL; Wharton JM; Wilkinson WE; Friedman IM; Claypool WD; Karim A; Kowalski KG; McDonald SJ; Gardiner P; Pritchett EL
Clin Pharmacol Ther; 1992 Apr; 51(4):371-8. PubMed ID: 1563207
[TBL] [Abstract][Full Text] [Related]
45. First human studies on the safety and antitussive activity of vadocaine hydrochloride.
Karttunen P; Tukiainen H; Uusitupa M; Männistö PT
Arzneimittelforschung; 1988 Apr; 38(4A):631-4. PubMed ID: 3395401
[TBL] [Abstract][Full Text] [Related]
46. XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study.
Deloche C; Lopez-Lazaro L; Mouz S; Perino J; Abadie C; Combette JM
Pharmacol Res Perspect; 2014 Feb; 2(1):e00020. PubMed ID: 25505576
[TBL] [Abstract][Full Text] [Related]
47. Assessment of the safety margin of vadocaine hydrochloride in man.
Karttunen P; Uusitupa M; Helin M; Tukiainen H; Silvasti M
Arzneimittelforschung; 1988 Apr; 38(4A):642-6. PubMed ID: 3395404
[TBL] [Abstract][Full Text] [Related]
48. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers.
Benedict CR; Arbogast R; Martin L; Patton L; Morrill B; Hahne W
J Cardiovasc Pharmacol; 1996 Jul; 28(1):53-9. PubMed ID: 8797136
[TBL] [Abstract][Full Text] [Related]
49. Safety and tolerance of intravenous nimodipine.
Sramek JJ; Heller AH; Sundaresan PR; Lettieri J; Sawin S; Cutler NR
Ann Pharmacother; 1994 Oct; 28(10):1143-8. PubMed ID: 7841566
[TBL] [Abstract][Full Text] [Related]
50. A phase I, dose-escalation trial evaluating the safety and efficacy of emulsified isoflurane in healthy human volunteers.
Huang H; Li R; Liu J; Zhang W; Liao T; Yi X
Anesthesiology; 2014 Mar; 120(3):614-25. PubMed ID: 24162462
[TBL] [Abstract][Full Text] [Related]
51. Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers.
Eldon MA; Smith RA; Leese PT; Daigle AE; Katz DV; Richieri SP
J Clin Pharmacol; 1990 Apr; 30(4):352-7. PubMed ID: 2140370
[TBL] [Abstract][Full Text] [Related]
52. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers.
Iuliucci JD; Oliver SD; Morley S; Ward C; Ward J; Dalgarno D; Clackson T; Berger HJ
J Clin Pharmacol; 2001 Aug; 41(8):870-9. PubMed ID: 11504275
[TBL] [Abstract][Full Text] [Related]
53. An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations.
Ivanova A; Murphy M
J Biopharm Stat; 2009; 19(2):247-55. PubMed ID: 19212877
[TBL] [Abstract][Full Text] [Related]
54. Lubeluzole. JK 8792, R 87926, Prosynap.
Drugs R D; 1999 Jan; 1(1):29-31. PubMed ID: 10565978
[No Abstract] [Full Text] [Related]
55. A phase I study of oxidized raffinose cross-linked human hemoglobin.
Carmichael FJ; Ali AC; Campbell JA; Langlois SF; Biro GP; Willan AR; Pierce CH; Greenburg AG
Crit Care Med; 2000 Jul; 28(7):2283-92. PubMed ID: 10921554
[TBL] [Abstract][Full Text] [Related]
56. Effect of paroxetine on the electrocardiogram.
Edwards JG; Goldie A; Papayanni-Papasthatis S
Psychopharmacology (Berl); 1989; 97(1):96-8. PubMed ID: 2523548
[TBL] [Abstract][Full Text] [Related]
57. Tolerability and pharmacokinetics of L-648,051. A leukotriene D4-receptor antagonist, in healthy volunteers.
Biollaz J; Stahl E; Hsieh JY; Distlerath L; Jaeger A; Leuenberger P; Schelling JL
Eur J Clin Pharmacol; 1988; 33(6):603-7. PubMed ID: 2835245
[TBL] [Abstract][Full Text] [Related]
58. [Cardiovascular tolerability of indalpine in therapeutic doses].
Jaillon P; Cheymol G; Alby JM; Ferreri M; Lecocq B
Therapie; 1986; 41(1):49-52. PubMed ID: 3704991
[No Abstract] [Full Text] [Related]
59. Hemodynamic and electrocardiographic effects of açaí berry in healthy volunteers: a randomized controlled trial.
Gale AM; Kaur R; Baker WL
Int J Cardiol; 2014 Jun; 174(2):421-3. PubMed ID: 24767759
[No Abstract] [Full Text] [Related]
60. Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist Vestipitant.
Brigandi RA; Russ SF; Petit C; Johnson B; Croy S; Hodsman P; Muller F
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):130-136. PubMed ID: 26097793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
